They are a type of medical treatment. Scientists make monoclonal antibodies, or mAbs, in a lab. They work like the natural antibodies your body makes to fight illness. They go out into your body ...

Y-mAbs Therapeutics, Inc Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022 ...

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s ...

Y-mAbs Therapeutics (NASDAQ:YMAB) lost ~6% on Tuesday after Bank of America downgraded the cancer drug developer to Underperform from Neutral, arguing that most of the market potential for the ...

Y-mAbs Therapeutics YMAB stock peaked at $54.1 in late 2020, fueled by high hopes for its cancer treatment, Omburtamab. However, the FDA's 2020 Refusal to File and subsequent Complete Response ...

Across the recent three months, 7 analysts have shared their insights on Y-mAbs Therapeutics (NASDAQ:YMAB), expressing a variety of opinions spanning from bullish to bearish. In the table below ...

A FDA advisory committee has blown a hole in Y-mAbs Therapeutics’ hopes of winning approval for its rare disease drug, delivering a damning 0-16 verdict on the question of whether the company ...

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and ...

In 2017, the number of monoclonal antibodies (mAbs) granted approval in the United States reached double-digits for the first time. Out of a total of 46 drugs approved by the US Food and Drug ...